At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 445 enrolled
Drug / intervention
montelukast sodiumdrug
Likely dose
montelukast sodium 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Montelukast Sodium (Singulair®), 4 or 5 mg/Day in Pediatric Subjects With Uncontrolled Asthma
In Brief
A Phase 4 clinical trial evaluating montelukast sodium for Asthma. Completed, enrolled 445 participants.
Detailed Summary
a study to describe patient and physician satisfaction with montelukast therapy for the control of asthma used either as monotherapy or in combination with inhaled corticosteroids
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
Primary CompletionOct 2008
First PostedJan 2009
TodayJul 2026
First PostedJan 30, 2009
Enrollment StartJun 1, 2006
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.4 years ago
Interventions
montelukast sodiumdrug
Montelukast 4-5 mg for 12 weeks, oral tablet